ClinicalTrials.gg
RecruitingNCT06102304Updated Oct 29, 2026

Myo-Electrical and Nerve Root Function Response to Focused Extracorpeal Shock Wave in Cervical Radiculopathy

An interventional study of Focused Extracorpeal Shock wave and Sham Extracorpeal shock wave in Cervical Radiculopathy, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 36 Years to 46 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 29, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
36 Years to 46 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Radiculopathy by Cairo University — 22 open to participants now, 22 under way, none of them phase 3. Radiculopathy · Cairo University.

Planned enrollment
Largest of 27
80 · median 45
Started
2026
with 12 others
No phase
26 of 36
15 open now
Primary completion
2026-11
later than 15 of 21 live
Registered
7th of 36
by date

Among the 36 studies in Radiculopathy by Cairo University, this one has the largest planned enrollment of the 27 interventional ones that give a count, is one of 13 that started in 2026, is one of 26 with no phase, reaches primary completion later than 15 of the 21 other live ones, and was the 7th registered.

Radiculopathy

488 studies on the registry are indexed under Radiculopathy; 145 are open to participants now.

Browse Radiculopathy studies →

Open to participants now

22 of the 36 studies in Radiculopathy by Cairo University are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 79 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 48 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 36 Years to 46 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Radiculopathy by Cairo University, or all of them as a file.
02

Study summary

BACKGROUND: Upper limb nerve root dysfunction with increased active myofascial trigger point in upper trapezius is common problem in patients with cervical radiculopathy.

The purpose of this study was to evaluate the effect of Extracorpeal shock wave on the myo-electric and nerve function responses in patients with cervical radiculopathy.

Read the detailed description

Randomized controlled clinical trial among Forty eight (48) patients with cervical radiculopathy.

They will be allocated randomly by sealed envelopes into two groups: Group (A): will receive a designed physical therapy program in addition to sham Extracorpeal shock wave on upper trapezius. Group (B): will receive Focused Extracorpeal shock wave on the active myofascial trigger points in upper trapezius in addition to the same physical therapy program as in group A.

Somatosensory evoked potential for upper limb median nerve will be applied using the Electromyography (EMG) device. Hand grip strength will be assessed using the handheld dynamometer (HHD) , Level of radiating pain will be assessed using the numeric rating scale , Pain and tenderness in upper trapezius muscle will be also assessed using Pressure pain threshold (PPT).

03

Conditions studied

  • Cervical Radiculopathy

Browse trials for

Keywords

  • Cervical Radiculopathy
  • Nerve root Dysfunction
  • Trigger points
  • Focused Extracorpeal Shock Wave
04

Who can participate

Ages eligible
36 Years to 46 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All patients suffer from unilateral discogenic cervical radiculopathy of lower cervical spine(C5-C6 and/ or C6-C7) as confirmed with MRI.
  2. All patients suffer from pain and tenderness on active trigger points of the upper trapezius .
  3. Age ranging from 36 to 46 years old.
  4. Duration of symptoms more than 3 months to avoid acute stage of inflammation.
  5. Side to side amplitude differences of 50% or more in DSSEPs measurement (Naguszewski et al.,2001)

Exclusion criteria

Exclusion Criteria:

  1. Posterior osteophytes
  2. Spinal canal stenosis
  3. Rheumatoid arthritis
  4. Vestibular insufficiency
  5. Osteoporosis
  6. Any signs or symptoms of myelopathy
  7. Any abnormalities of deep sensation
  8. Associated pathologies of upper cervical region or the upper limb that may cause overlapping with clinical findings as referred pain from costotransverse joint, rotator cuff tendonitis, cervical rib syndrome and entrapment neuropathy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Placebo comparator
    Sham Extracorpeal Shock Wave

    Control group (GA) Patients in (GA) will be treated by a designed physiotherapy program consisted of Myo-fascial release, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Median nerve neural glide techniques, Graduated strengthening exercises for the upper limb in addition to sham shockwave on the upper trapezius.

    Device: Sham Extracorpeal shock wave

  • Experimental
    Focused Extracorpeal Shock wave

    Patients in (GB) will be treated by Focused Extracorpeal shockwave on the trigger points of upper trapezius in addition to the same physiotherapy program as GA.

    Device: Focused Extracorpeal Shock wave

Interventions

  • DeviceFocused Extracorpeal Shock wave

    Focused Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band was applied as low energy 2 sessions per week for 4 weeks. (EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy) was used as a focused extracorporeal shock wave therapy apparatus.

  • DeviceSham Extracorpeal shock wave

    (EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy) was used as a focused extracorporeal shock wave therapy apparatus. The device will be used in the demo mood with no radiation or impulses applied.

06

What researchers measure

Primary outcomes

  1. Amplitude of median nerve dermatomal somatosensory evoked potential

    After the stimulation was performed and the traces were superimposed to ensure reproducibility, negative near field potential were detected and positive peak was detected to measure the peak to peak amplitude. This amplitude was measured. The distance between positive and negative peak , it is measures in millivolts (mV)

    Time frame: Baseline Assessment and Immediately Post Treatment.

  2. Distal Latency of median nerve dermatomal somatosensory evoked potential

    Distal latency is defined as the interval between the stimulation of a compound muscle or selective dermatome and the observed response. It is measured in meter per second (m/s)

    Time frame: Baseline Assessment and Immediately Post Treatment.

  3. Pain Pressure Threshold on upper trapezius

    Pain pressure Threshold (PPT) device will be used to detect tenderness and pain on the active myofascial trigger points on upper trapezius muscle. The 1-cm² rubber tip was applied perpendicularly over the myofascial trigger points and the power is switched on; a required pressure will be exerted on the site of myofascial trigger points by pressing the transducers firmly downwards. Measurements were recorded in kilograms of pressure per square centimeter (kg/cm\^2).

    Time frame: Baseline Assessment and Immediately Post Treatment.

  4. Hand grip Strength

    Jamar hydraulic hand dynamometer will be used, it is a quantitative and an objective measure of the isometric muscular strength of the hand grip. It is a portable dynamometer used as a valid and reliable tool to reflect the upper limb strength. This instrument is scored using force production in kilograms (0-90) or pounds (0-200). Maximum grip was the mean of three trials. For each patient the both sides were assessed before treatment to collect the normative value for each patient. Mean of Maximum grip was compared pre and post treatment for each patient

    Time frame: Baseline Assessment and Immediately Post Treatment.

  5. Level of radiating pain

    Numeric rating Scale (NRS) for pain will be used to assess level of pain radiating through the upper limb. Patients are asked to circle the number between 0 and 10 that fits best to their pain intensity . Zero usually represents 'no pain at all' whereas the upper limit represents 'the worst pain ever possible'.

    Time frame: Baseline Assessment and Immediately Post Treatment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2026, 5 months after the start.

Of 205 non-industry interventional studies with no phase under Radiculopathy, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's planned 5 months is below that.

Counting every sponsor, half of 217 studies reached it within 12 months; a quarter within 5 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: start Apr 2025 → May 2026, primary completion Nov 2025 → Nov 2026 and completion Jan 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2023
First posted
Oct 26, 2023
StartActual
May 6, 2026was Apr 2025
Primary completionEst.
Nov 5, 2026was Nov 2025
CompletionEst.
Nov 18, 2026was Jan 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 6, 2025→May 6, 2026
Oct 29, 2026
Primary completion
Nov 29, 2025→Nov 5, 2026
Oct 29, 2026
Study completion
Jan 18, 2026→Nov 18, 2026
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Start date Apr 6, 2025→May 6, 2026
    Primary completion Nov 29, 2025→Nov 5, 2026
    Study completion Jan 18, 2026→Nov 18, 2026
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06102304
Lead sponsor
Cairo University
Responsible party
Engy Badreldin Saleh Moustafa, PhD (Dr., Cairo University) — Principal investigator
First posted
Oct 26, 2023
Start date
May 6, 2026
Primary completion
Nov 5, 2026 (estimated)
Completion
Nov 18, 2026 (estimated)
Last update
Oct 29, 2026

Study contacts

Engy BadrEldin S Moustafa, PhD
Contact
engybm.saleh@cu.edu.eg
00201099445112
Moshera H. Darwish, PhD
Contact
dr.moshera11@yahoo.com
00201015163617
Engy BadrEldin S Moustafa, PhD
principal investigator · Faculty of Physical Therapy, Cairo University, Egypt

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion